Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

Seminars in oncology - 1 Oct 2005

Momparler Richard L

Abstract excerpt

Epigenetic events, such as aberrant DNA methylation, have been demonstrated to silence the expression of many genes that suppress malignancy. Since the event is reversible, it is an interesting target for intervention with specific inhibitors of DNA methylation, such as 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine). 5-AZA-CdR is a prodrug that requires activation via phosphorylation by deoxcytidine kinase. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Decitabine

Share to Models, Chemical

Share to Prodrugs

Share to S Phase

Source

Identifiers

PMID: 16210084
DOI: 10.1053/j.seminoncol.2005.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).PMID 16210084Read ↗

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapySemantic proximity Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Epigenetic anti-cancer treatment with a stabilized carbocyclic Decitabine analogueSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Novel prodrugs of decitabine with greater metabolic stability and less toxicitySemantic proximity Read ↗

Demethylating agents in myeloid malignanciesSemantic proximity Read ↗

DecitabineSemantic proximity Read ↗

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.Semantic proximity Read ↗

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)Semantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.